title: Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
abstract: Despite recent progress in antithrombotic therapy, there is still an unmet medical need for safe and orally available anticoagulants. The coagulation enzyme Factor Xa (FXa) is a particularly promising target, and recent efforts in this field have focused on the identification of small-molecule inhibitors with good oral bioavailability. We identified oxazolidinone derivatives as a new class of potent FXa inhibitors. Lead optimization led to the discovery of BAY 59-7939 (5), a highly potent and selective, direct FXa inhibitor with excellent in vivo antithrombotic activity. The X-ray crystal structure of 5 in complex with human FXa clarified the binding mode and the stringent requirements for high affinity. The interaction of the neutral ligand chlorothiophene in the S1 subsite allows for the combination of good oral bioavailability and high potency for nonbasic 5. Compound 5 is currently under clinical development for the prevention and treatment of thromboembolic diseases.
authors.affiliation: Bayer HealthCare AG, D-42096 Wuppertal, Germany. susane.roehrig@bayerhealthcare.com
authors.forename: Susanne
authors.initials: S
authors.lastname: Roehrig
authors.forename: Alexander
authors.initials: A
authors.lastname: Straub
authors.forename: Jens
authors.initials: J
authors.lastname: Pohlmann
authors.forename: Thomas
authors.initials: T
authors.lastname: Lampe
authors.forename: Josef
authors.initials: J
authors.lastname: Pernerstorfer
authors.forename: Karl-Heinz
authors.initials: KH
authors.lastname: Schlemmer
authors.forename: Peter
authors.initials: P
authors.lastname: Reinemer
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Perzborn
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000925:Anticoagulants / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology; D001682:Biological Availability; D018360:Crystallography, X-Ray; D004285:Dogs; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D006207:Half-Life; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008958:Models, Molecular; D009025:Morpholines / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D011517:Prothrombin Time; D051381:Rats; D017208:Rats, Wistar; D000069552:Rivaroxaban; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D013876:Thiophenes / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban